688062 邁威生物
按盤價 
26.600 -0.330 (-1.225%) | 2026/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 127,597 | 184.89% | 662,516 | 199,782 | 127,836 | 27,728 | |
| 減：營業總成本 | 356,747 | 6.14% | 1,634,418 | 1,259,798 | 1,175,895 | 993,419 | |
| 其中:營業成本 | 30,433 | 205.07% | 64,464 | 28,952 | 1,370 | 71 | |
| 財務費用 | 29,784 | 72.29% | 87,067 | 36,726 | (33,411) | (34,764) | |
| 資產減值損失 | (1,210) | -55.50% | (11,264) | (5,527) | (9,488) | (1,940) | |
| 公允價值變動收益 | -- | -- | 1,122 | 493 | (3,043) | 1,082 | |
| 投資收益 | (3,423) | 134.58% | (9,602) | (4,219) | (1,649) | 714 | |
| 其中：對聯營企業和合營企業的投資收益 | (3,866) | 123.95% | (10,562) | (7,058) | (2,594) | (476) | |
| 營業利潤 | (238,882) | -17.92% | (955,318) | (1,043,480) | (1,052,579) | (958,139) | |
| 利潤總額 | (240,151) | -17.87% | (956,394) | (1,047,471) | (1,055,288) | (958,126) | |
| 減：所得稅費用 | 2,892 | 5,237.67% | 15,864 | (907) | 3,524 | -- | |
| 淨利潤 | (243,043) | -16.90% | (972,258) | (1,046,565) | (1,058,811) | (958,126) | |
| 減：非控股權益 | (1,099) | 50.69% | (2,924) | (2,645) | (5,379) | (2,891) | |
| 股東淨利潤 | (241,944) | -17.07% | (969,334) | (1,043,919) | (1,053,433) | (955,235) | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.610 | -16.44% | -2.430 | -2.610 | -2.640 | -2.440 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | -- | |
| 每股淨資產 (元) * | 0.267 | -91.64% | 0.875 | 3.926 | 6.466 | 8.798 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 05/06/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
